Tekmira Pharmaceuticals Corp (TKMR.OQ)

TKMR.OQ

About

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop... (more)

Buy/Sell

» Analyst Consensus

Overall

No Ratios Available.

Financials

	TKMR.OQ	Industry	Sector
P/E (TTM):	--	54.65	35.85
EPS (TTM):	--	--	--
ROI:	--	0.83	18.76
ROE:	--	1.79	19.57

Latest News about TKMR.OQ

» More TKMR.OQ News

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - TEKMIRA PHARMACEUTICALS CORPORATION (TKM-T) Provider: Thomson Reuters Stock Report	$25.00 Buy
Tekmira Pharmaceuticals Corp. (TKM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
TEKMIRA PHARMACEUTICALS CP (TKMR) 12-months forecast Provider: Pechala's Reports	$15.00 Buy
Tekmira Pharmaceuticals Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
ValuEngine Detailed Valuation Report for TKMR Provider: ValuEngine, Inc.	$127.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.